Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Abstract B33: CRLX101, an investigational nanoparticle-drug conjugate, localizes in human tumors and not in adjacent healthy tissue after intravenous dosing

Andrew Clark, Devin T. Wiley, Jonathan E. Zuckerman, Paul Webster, Joseph Chao, James Lin, Yun Yen, Mark E. Davis, Scott Eliasof

Mol Cancer Ther (2015) 14 (12_Supplement_2): B33.

https://doi.org/10.1158/1535-7163.TARG-15-B33

Published: 01 December 2015

View article titled, Abstract B33: CRLX101, an investigational nanoparticle-drug conjugate, localizes in human tumors and not in adjacent healthy tissue after intravenous dosing

Journal Articles

Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca²⁺/Calmodulin-Dependent Protein Kinase II

Zhipeng Meng, Tao Li, Xiaoxiao Ma, Xiaoqiong Wang, Carl Van Ness, Yichao Gan, Hong Zhou, Jinfen Tang, Guiyu Lou, Yafan Wang, Jun Wu, Yun Yen, Rongzhen Xu, Wendong Huang

Mol Cancer Ther (2013) 12 (10): 2067–2077.

https://doi.org/10.1158/1535-7163.MCT-13-0314

Published: 07 October 2013

View article titled, Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II

Includes: Supplementary data

Journal Articles

Abstract A97: Final phase 1/2a results evaluating the cyclodextrin-containing nanoparticle CRLX101 in patients with advanced solid tumor malignancies.

Yun Yen, Lori A. Coerver, Edward G. Garmey, D. Lynn Kalinoski, Marianna Koczywas, James A. Neidhart, Jeffrey D. Neidhart, Joanna J. Peterkin, Ramesh K. Ramanathan, John Ryan, Glen J. Weiss

Mol Cancer Ther (2011) 10 (11_Supplement): A97.

https://doi.org/10.1158/1535-7163.TARG-11-A97

Published: 12 November 2011

View article titled, Abstract A97: Final phase 1/2a results evaluating the cyclodextrin-containing nanoparticle CRLX101 in patients with advanced solid tumor malignancies.

Journal Articles

p53R2 Inhibits the Proliferation of Human Cancer Cells in Association with Cell-Cycle Arrest

Keqiang Zhang, Jun Wu, Xiwei Wu, Xiaochen Wang, Yan Wang, Ning Zhou, Mei-ling Kuo, Xiyong Liu, Bingsen Zhou, Lufen Chang, David Ann, Yun Yen

Mol Cancer Ther (2011) 10 (2): 269–278.

https://doi.org/10.1158/1535-7163.MCT-10-0728

Published: 08 February 2011

View article titled, p53R2 Inhibits the Proliferation of Human Cancer Cells in Association with Cell-Cycle Arrest

Includes: Supplementary data

Journal Articles

Structural Basis on the Dityrosyl-Diiron Radical Cluster and the Functional Differences of Human Ribonucleotide Reductase Small Subunits hp53R2 and hRRM2

Bingsen Zhou, Leila Su, Yate-Ching Yuan, Frank Un, Norby Wang, Madhukar Patel, Bixin Xi, Shuya Hu, Yun Yen

Mol Cancer Ther (2010) 9 (6): 1669–1679.

https://doi.org/10.1158/1535-7163.MCT-10-0023

Published: 09 June 2010

View article titled, Structural Basis on the Dityrosyl-Diiron Radical Cluster and the Functional Differences of Human Ribonucleotide Reductase Small Subunits hp53R2 and hRRM2

Journal Articles

A Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of GTI2040 (GTI), a novel ribonucleotide reductase inhibitor in combination with gemcitabine (Gem) in adult patients (pts) with advanced solid tumors.

Chris Takimoto, Quincy Chu, Yun Yen, Patricia O'Rourke, Joshua Cooper, Sam Pardo, Anthony Tolcher, Amita Patnaik, Kyriakos Papadopoulos, Muralidhar Beeram, Alejandro Ricart, Chia-Chi Lin, Alain Mita, Emiliano Calvo, Igor Espinoza-Delgado, Jamie Zwiebel, John Sarantopoulos

Mol Cancer Ther (2007) 6 (11_Supplement): C160.

Published: 01 November 2007

View article titled, A Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of GTI2040 (GTI), a novel ribonucleotide reductase inhibitor in combination with gemcitabine (Gem) in adult patients (pts) with advanced solid tumors.

Journal Articles

SUMOylation plays a role in gemcitabine- and bortezomib-induced cytotoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone

Vincent Chung, Bingsen Zhou, Xiyong Liu, Lijun Zhu, Lee M. Boo, Ha-Van Nguyen, David K. Ann, Jing Song, Yuan Chen, Yun Yen

Mol Cancer Ther (2006) 5 (3): 533–540.

https://doi.org/10.1158/1535-7163.MCT-05-0290

Published: 16 March 2006

View article titled, SUMOylation plays a role in gemcitabine- and bortezomib-induced cytotoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone

Journal Articles

A Ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase

Jimin Shao, Bingsen Zhou, Angel J. Di Bilio, Lijun Zhu, Tieli Wang, Christina Qi, Jennifer Shih, Yun Yen

Mol Cancer Ther (2006) 5 (3): 586–592.

https://doi.org/10.1158/1535-7163.MCT-05-0384

Published: 16 March 2006

View article titled, A Ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase

Journal Articles

A dityrosyl-diiron radical cofactor center is essential for human ribonucleotide reductases

Bingsen Zhou, Jimin Shao, Leila Su, Yate-Ching Yuan, Christina Qi, Jennifer Shih, Bixin Xi, Bernard Chu, Yun Yen

Mol Cancer Ther (2005) 4 (12): 1830–1836.

https://doi.org/10.1158/1535-7163.MCT-05-0273

Published: 22 December 2005

View article titled, A dityrosyl-diiron radical cofactor center is essential for human ribonucleotide reductases

Journal Articles

Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma

Lijun Zhu, George Somlo, Bingsen Zhou, Jimin Shao, Victoria Bedell, Marilyn L. Slovak, Xiyong Liu, Jianhong Luo, Yun Yen

Mol Cancer Ther (2005) 4 (5): 787–798.

https://doi.org/10.1158/1535-7163.MCT-04-0330

Published: 16 May 2005

View article titled, Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma

NARROW

Abstract B33: CRLX101, an investigational nanoparticle-drug conjugate, localizes in human tumors and not in adjacent healthy tissue after intravenous dosing

Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca²⁺/Calmodulin-Dependent Protein Kinase II

Abstract A97: Final phase 1/2a results evaluating the cyclodextrin-containing nanoparticle CRLX101 in patients with advanced solid tumor malignancies.

p53R2 Inhibits the Proliferation of Human Cancer Cells in Association with Cell-Cycle Arrest

Structural Basis on the Dityrosyl-Diiron Radical Cluster and the Functional Differences of Human Ribonucleotide Reductase Small Subunits hp53R2 and hRRM2

A Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of GTI2040 (GTI), a novel ribonucleotide reductase inhibitor in combination with gemcitabine (Gem) in adult patients (pts) with advanced solid tumors.

SUMOylation plays a role in gemcitabine- and bortezomib-induced cytotoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone

A Ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase

A dityrosyl-diiron radical cofactor center is essential for human ribonucleotide reductases

Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only